Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.
Serrano C, et al. Among authors: rubin bp.
Br J Cancer. 2019 Mar;120(6):612-620. doi: 10.1038/s41416-019-0389-6. Epub 2019 Feb 22.
Br J Cancer. 2019.
PMID: 30792533
Free PMC article.